Citations

Clear

3138 citation(s) found for "Smith, AM".

An adult onset case of alpha‐methyl‐acyl‐CoA racemase deficiency
Smith, Emily H., Gavrilov, Dimitar K. , Oglesbee, Devin , Freeman, William D. , Vavra, Michael W, Matern, Dietrich , Tortorelli, Silvia , Gavrilov, Dimitar , Oglesbee, Devin , Freeman, William D

Mayo Clinic

Journal of Inherited Metabolic Disease | September 3, 2010 | Volume: 33 | Issue: S3 | Pages: 349-353

10.1007/s10545-010-9183-6 | PMID 20821052 Get It

Abstractα‐Methyl‐acyl‐CoA‐racemase (AMACR) deficiency (OMIM 604489) is a rare peroxisomal disorder with a variable age of onset from infancy to late adulthood. We describe a 45‐year‐old male with a history of seizures who presented with relapsing encephalopathy. Laboratory studies revealed an elevated serum pristanic acid concentration, an elevated pristanic/phytanic acid ratio, as well as the previously described homozygous mutation in the AMACR gene, c.154T>C, consistent with AMACR deficiency. This homozygous mutation is associated with a variable phenotype ranging from neonatal cholestasis to late‐onset sensorimotor neuropathy. Dietary pristanic acid restriction was attempted to improve clinical status and the patient has remained in remission for more than 16 months.
Evidence for Amino Acid Changes in a 57-Base-Pair Region of the Highly Conserved Matrix Gene of Pandemic (H1N1) 2009 Influenza A Virus
Dhiman, Neelam , Espy, Mark J., Irish, Cole L., Wright, Patty A., Smith, Thomas F., Pritt, Bobbi S. , Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | August 5, 2010 | Volume: 48 | Issue: 10 | Pages: 3817-3819

10.1128/jcm.01237-10 | PMID 20686094 Get It

Why Some Disabled Adults In Medicaid Face Large Out-Of-Pocket Expenses
Shah, Nilay D. , Burns, Marguerite E , Smith, Maureen P.

Mayo Clinic

Health Affairs | August 2, 2010 | Volume: 29 | Issue: 8 | Pages: 1517-1522

10.1377/hlthaff.2009.0147 | PMID 20679656 Get It

Capecitabine and Temozolomide: Design, Implementation, and Preliminary Outcomes From a Pilot Project to Ensure Safe Prescribing of Oral Chemotherapy
Jatoi, Aminah , Smith, Emily L., Gunderson, Heidi D, Hartgers, Mindy L., Looker, Sherry, Santana-Dávila, Rafael , McWilliams, Robert R.

Mayo Clinic

Journal of Oncology Practice | July 16, 2010 | Volume: 6 | Issue: 4 | Pages: 210-212

10.1200/jop.200031 | PMID 21037876 Get It

Without adequate safety measures, oral chemotherapy can lead to undetected dosing errors. The Mayo Clinic launched a project to ensure that all capecitabine and temozolomide prescriptions receive an independent double check.
PL‐03‐02: Neuropychological approaches for early detection and characterization of dementing disorders
Smith, Glenn E.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2010.05.356 Get It

IC‐01‐01: Antemortem PiB binding correlates with postmortem amyloid density in a case with DLB on region of interest analysis
Yang, Chunhui , Reyes, Denise A., Lowe, Val J. , Aggarwal, Neelum T. , Petersen, Ronald C. , Kantarci, Kejal , Schneider, Julie A. , Senjem, Matthew L. , Barnes, Lisa L. , Bennett, David A. , Smith, Glenn E. , Knopman, David S. , Jack, Clifford R. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2010.05.007 Get It

Adult hematopoietic stem cells require NKAP for maintenance and survival
Pajerowski, Anthony G., Shapiro, Michael J. , Gwin, Kimberly, Sundsbak, Rhianna S., Nelson-Holte, Molly, Medina, Kay L. , Shapiro, Virginia Smith

Mayo Clinic

Blood | July 7, 2010 | Volume: 116 | Issue: 15 | Pages: 2684-2693

10.1182/blood-2010-02-268391 | PMID 20610818 Get It

Abstract Steady-state hematopoiesis is sustained through differentiation balanced with proliferation and self-renewal of hematopoietic stem cells (HSCs). Disruption of this balance can lead to hematopoietic failure, as hematopoietic differentiation without self-renewal leads to loss of the HSC pool. We find that conditional knockout mice that delete the transcriptional repressor NKAP in HSCs and all hematopoietic lineages during embryonic development exhibit perinatal lethality and abrogation of hematopoiesis as demonstrated by multilineage defects in lymphocyte, granulocyte, erythrocyte and megakaryocyte development. Inducible deletion of NKAP in adult mice leads to lethality within 2 weeks, at which point hematopoiesis in the bone marrow has halted and HSCs have disappeared. This hematopoietic failure and lethality is cell intrinsic, as radiation chimeras reconstituted with inducible Mx1-cre NKAP conditional knockout bone marrow also succumb with a similar time course. Even in the context of a completely normal bone marrow environment using mixed radiation chimeras, NKAP deletion results in HSC failure. NKAP deletion leads to decreased proliferation and increased apoptosis of HSCs, which is likely due to increased expression of the cyclin-dependent kinase inhibitors p21Cip1/Waf1 and p19Ink4d. These data establish NKAP as one of a very small number of transcriptional regulators that is absolutely required for adult HSC maintenance and survival.
Refining Rehabilitation With Proprioception Training
Laskowski, Edward R. , Newcomer‐Aney, Karen, Smith, Jay

Mayo Clinic

The Physician and Sportsmedicine | May 13, 2010 | Volume: 25 | Issue: 10 | Pages: 89-102

10.3810/psm.1997.10.1476 | PMID 20086861 Get It

Weight Training Injuries
Reeves, Ronald K. , Laskowski, Edward R. , Smith, Jay

Mayo Clinic

The Physician and Sportsmedicine | May 13, 2010 | Volume: 26 | Issue: 2 | Pages: 67-96

10.3810/psm.1998.02.939 | PMID 20086781 Get It

Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses
Hoelzinger, Dominique B. , Smith, Shannon E., Mirza, Noweeda, Manrique, Soraya Zorro, Lustgarten, Joseph, Dominguez, Ana Lucía

Mayo Clinic

The Journal of Immunology | May 7, 2010 | Volume: 184 | Issue: 12 | Pages: 6833-6842

10.4049/jimmunol.0904084 | PMID 20483762 Get It

Abstract Intratumoral accumulation of T regulatory cells (Tregs) creates an immunosuppressive environment that reduces the efficacy of antitumor immunotherapy. The immunosuppressive milieu within tumors is largely brought about by the presence of Tregs, which maintain self-tolerance by directly inhibiting T cells, NK cells, and dendritic cells. Depletion of Tregs enhances antitumor immune responses; however, current depletion therapies also affect the function of CD4 and CD8 T effector cells. Previous studies from our laboratory indicate that intratumoral delivery of CpG-ODN strongly reduces the levels of Tregs within the tumor, which is mainly mediated by IL-6. Because IL-6 promotes growth of some human cancers, alternate pathways to inactivate Tregs were sought through microarray analysis, resulting in gene candidates that can be exploited to modulate the function of Tregs. Analysis of these candidates indicates that neutralization of chemokine (C-C motif) ligand 1 (CCL1) prevented de novo conversion and suppressive function of Tregs without affecting the function of T effector cells. The combination of CpG-ODN and anti-CCL1 treatments induced complete rejection of tumors in BALB-neuT tolerant mice, and result in the generation of long-term protective memory responses. Tumor rejection correlated with changes in the lymphocyte composition within the tumor; we observed decreased Treg numbers and a concomitant accumulation of tumoricidal cells such as CD8+NKG2D+ and NK cells. These studies demonstrate that neutralization of CCL1 can be used as an adjuvant to antitumor immunotherapy, as a means of reversing the immunosuppressive function of Tregs without compromising T cell effector function.